Testis Cancer
10
1
1
5
Key Insights
Highlights
Success Rate
83% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
10.0%
1 terminated out of 10 trials
83.3%
-3.2% vs benchmark
0%
0 trials in Phase 3/4
20%
1 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (10)
Enhancing Readability of Lay Abstracts and Summaries for Medical Knowledge Using Generative Artificial Intelligence (BRIDGE AI 3)
Helping Young People With Testicular Cancer Using Virtual and Extended Reality
Virtual Testis Cancer Lay Support and Survivorship Aim 2
Role of Axumin PET Scan in Germ Cell Tumor
The Registry of Oncology Outcomes Associated with Testing and Treatment
Mental Health of Men Before and After Testicular Cancer Treatment
The Man Van Project
A Biobehavioral Intervention for Young Men With Testicular Cancer
Study of the Hypomethylating Drug Guadecitabine (SGI-110) Plus Cisplatin in Relapsed Refractory Germ Cell Tumors
Brentuximab Vedotin in Relapsed/Refractory Germ Cell Tumors